Titles
- ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin1
- Abuse and neglect: CMS should strengthen reporting requirements to better protect individuals receiving hospice care : report to the Honorable Charles E. Grassley, United States Senate1
- Acceptance and filing reviews for premarket approval applications (PMAs): guidance for industry and Food and Drug Administration staff1
- Access and use of electronic health information by individuals with cancer: 2017-20181
- Access to Medicare Part D plans: a comparison of metropolitan and nonmetropolitan areas1
- Access to preventive services without cost-sharing: evidence from the Affordable Care Act1
- Achieving behavioral health care integration in rural America1
- Acne vulgaris: establishing effectiveness of drugs intended for treatment1
- Action level for inorganic arsenic in apple juice: guidance for industry1
- Acute myeloid leukemia: developing drugs and biological products for treatment : guidance for industry1
- Adaptive designs for clinical trials of drugs and biologics1
- Addressing social determinants of health: examples of successful evidence-based strategies and current federal efforts1
- Addressing the direct care workforce shortage: a bipartisan call to action1
- Adjusting for covariates in randomized clinical trials for drugs and biological products: guidance for industry1
- Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff1
- Adolescent and young adult substance use: federal grants for prevention, treatment, and recovery services and for research : report to Congressional committees1
- Advance care planning among Medicare fee-for-service beneficiaries and practitioners: final report1
- Advanced prostate cancer: developing gonadotropin-releasing hormone analogues1
- Advancement of emerging technology applications for pharmaceutical innovation and modernization1
- Advancing comprehensive primary care in Medicaid1